Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.50 |
| ▸ | IL6 | P05231 | 8/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26347339 | 0.98 | TLR7 (0.52) | TLR7IL6 | |
| SCHEMBL26347917 | 0.97 | TLR7 (0.48) | TLR7IL6 | |
| SCHEMBL26347921 | 0.97 | TLR7 (0.48) | TLR7IL6 | |
| SCHEMBL26347881 | 0.95 | TLR7 (0.49) | TLR7IL6 | |
| SCHEMBL26362026 | 0.95 | TLR7 (0.49) | TLR7IL6 | |
| SCHEMBL26360403 | 0.95 | TLR7 (0.49) | TLR7IL6 | |
| SCHEMBL26356048 | 0.94 | TLR7 (0.53) | TLR7IL6 | |
| SCHEMBL26355947 | 0.93 | TLR7 (0.51) | TLR7IL6 | |
| SCHEMBL26360242 | 0.93 | TLR7 (0.52) | TLR7IL6 | |
| SCHEMBL26347360 | 0.93 | TLR7 (0.52) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TLR7 4/4885IL6 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.